J-ALEX primary endpoint: PFS by IRF (ITT)
Nokihara, et al, ASCO 2016 (Abs. 9008)
HR=0.34 (0.17–0.71)
p<0.0001
Alectinib (n=103)
Crizotinib (n=104)
1.0
0.8
0.6
0.4
0.2
0
0
PFS estimate
27
9
3
21
15
Time (months)
24
6
18
12
10.2 (8.2–12.0)
NR (20.3–NR)
INDICACIÓN NO APROBADA, EN INVESTIGACIÓN
